Top

Published in:

Open Access 01-12-2016 | Original Article

Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice

Authors: Yang Yao, Weimin Miao, Zhijia Liu, Wei Han, Kaibin Shi, Yi Shen, Handong Li, Qiang Liu, Ying Fu, DeRen Huang, Fu-Dong Shi

Published in: Translational Stroke Research | Issue 6/2016

Abstract

Oxidative stress plays an important role in cerebral ischemia–reperfusion injury. Dimethyl fumarate (DMF) and its primary metabolite monomethyl fumarate (MMF) are antioxidant agents that can activate the nuclear factor erythroid-2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway and induce the expression of antioxidant proteins. Here, we evaluated the impact of DMF and MMF on ischemia-induced brain injury and whether the Nrf2 pathway mediates the effects provided by DMF and MMF in cerebral ischemia–reperfusion injury. Using a mouse model of transient focal brain ischemia, we show that DMF and MMF significantly reduce neurological deficits, infarct volume, brain edema, and cell death. Further, DMF and MMF suppress glial activation following brain ischemia. Importantly, the protection of DMF and MMF was mostly evident during the subacute stage and was abolished in Nrf2^−/− mice, indicating that the Nrf2 pathway is required for the beneficial effects of DMF and MMF. Together, our data indicate that DMF and MMF have therapeutic potential in cerebral ischemia–reperfusion injury and their protective role is likely mediated by the Nrf2 pathway.

Available only for authorised users

Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245–54.PubMedPubMedCentralCrossRef

Sun N, Keep RF, Hua Y, Xi G. Critical role of the sphingolipid pathway in stroke: a review of current utility and potential therapeutic targets. Transl Stroke Res. 2016. doi:10.1007/s12975-016-0477-3

Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368(10):893–903. doi:10.1056/NEJMoa1214300.PubMedPubMedCentralCrossRef

Grotta JC, Hacke W. Stroke neurologist’s perspective on the new endovascular trials. Stroke. 2015;46(6):1447–52. doi:10.1161/STROKEAHA.115.008384.PubMedCrossRef

Pundik S, Xu K, Sundararajan S. Reperfusion brain injury: focus on cellular bioenergetics. Neurology. 2012;79(13 Suppl 1):S44–51. doi:10.1212/WNL.0b013e3182695a14.PubMedCrossRef

Ahnstedt H, Sweet J, Cruden P, Bishop N, Cipolla MJ. Effects of early post-ischemic reperfusion and tPA on cerebrovascular function and nitrosative stress in female rats. Transl Stroke Res. 2016;7(3):228–38. doi:10.1007/s12975-016-0468-4.PubMedCrossRef

Liesz A, Kleinschnitz C. Regulatory T cells in post-stroke immune homeostasis. Transl Stroke Res. 2016;7(4):313–21. doi:10.1007/s12975-016-0465-7.PubMedCrossRef

Nakata M, Nakagomi T, Maeda M, Nakano-Doi A, Momota Y, Matsuyama T. Induction of perivascular neural stem cells and possible contribution to neurogenesis following transient brain ischemia/reperfusion injury. Transl Stroke Res. 2016. doi:10.1007/s12975-016-0479-1.

Margaill I, Plotkine M, Lerouet D. Antioxidant strategies in the treatment of stroke. Free Radic Biol Med. 2005;39(4):429–43. doi:10.1016/j.freeradbiomed.2005.05.003.PubMedCrossRef

10.

Amaro S, Chamorro A. Translational stroke research of the combination of thrombolysis and antioxidant therapy. Stroke. 2011;42(5):1495–9. doi:10.1161/STROKEAHA.111.615039.PubMedCrossRef

11.

Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008;39(6):1751–8. doi:10.1161/STROKEAHA.107.503334.PubMedCrossRef

12.

Macleod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke. 2008;39(10):2824–9. doi:10.1161/STROKEAHA.108.515957.PubMedCrossRef

13.

Kahles T, Brandes RP. NADPH oxidases as therapeutic targets in ischemic stroke. Cell Mol Life Sci. 2012;69(14):2345–63. doi:10.1007/s00018-012-1011-8.PubMedCrossRef

14.

Moretti A, Ferrari F, Villa RF. Neuroprotection for ischaemic stroke: current status and challenges. Pharmacol Ther. 2015;146:23–34. doi:10.1016/j.pharmthera.2014.09.003.PubMedCrossRef

15.

Kent TA, Mandava P. Embracing biological and methodological variance in a new approach to pre-clinical stroke testing. Transl Stroke Res. 2016;7(4):274–83. doi:10.1007/s12975-016-0463-9.PubMedCrossRef

16.

Salmen A, Gold R. Mode of action and clinical studies with fumarates in multiple sclerosis. Exp Neurol. 2014;262 Pt A:52–6. doi:10.1016/j.expneurol.2014.02.015.PubMedCrossRef

17.

Ohl K, Tenbrock K, Kipp M. Oxidative stress in multiple sclerosis: central and peripheral mode of action. Exp Neurol. 2015. doi:10.1016/j.expneurol.2015.11.010.

18.

Kastrati I, Siklos MA, Calderon-Gierszal EL, El-Shennawy L, Georgieva G, Thayer EN et al. Dimethyl fumarate inhibits the nuclear factor kappaB pathway in breast cancer cells by covalent modification of p65. J Biol Chem. 2015. doi:10.1074/jbc.M115.679704

19.

Jing X, Shi H, Zhang C, Ren M, Han M, Wei X, et al. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson’s disease by enhancing Nrf2 activity. Neuroscience. 2015;286:131–40. doi:10.1016/j.neuroscience.2014.11.047.PubMedCrossRef

20.

Zhao X, Sun G, Zhang J, Ting SM, Gonzales N, Aronowski J. Dimethyl fumarate protects brain from damage produced by intracerebral hemorrhage by mechanism involving Nrf2. Stroke. 2015;46(7):1923–8. doi:10.1161/STROKEAHA.115.009398.PubMedPubMedCentralCrossRef

21.

Iniaghe LO, Krafft PR, Klebe DW, Omogbai EK, Zhang JH, Tang J. Dimethyl fumarate confers neuroprotection by casein kinase 2 phosphorylation of Nrf2 in murine intracerebral hemorrhage. Neurobiol Dis. 2015;82:349–58. doi:10.1016/j.nbd.2015.07.001.PubMedPubMedCentralCrossRef

22.

Kunze R, Urrutia A, Hoffmann A, Liu H, Helluy X, Pham M, et al. Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity. Exp Neurol. 2015;266:99–111. doi:10.1016/j.expneurol.2015.02.022.PubMedCrossRef

23.

Gillard GO, Collette B, Anderson J, Chao J, Scannevin RH, Huss DJ, et al. DMF, but not other fumarates, inhibits NF-kappaB activity in vitro in an Nrf2-independent manner. J Neuroimmunol. 2015;283:74–85. doi:10.1016/j.jneuroim.2015.04.006.PubMedCrossRef

24.

Wallbrecht K, Drick N, Hund AC, Schon MP. Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions. Exp Dermatol. 2011;20(12):980–5. doi:10.1111/j.1600-0625.2011.01376.x.PubMedCrossRef

25.

Skoko JJ, Wakabayashi N, Noda K, Kimura S, Tobita K, Shigemura N, et al. Loss of Nrf2 in mice evokes a congenital intrahepatic shunt that alters hepatic oxygen and protein expression gradients and toxicity. Toxicol Sci. 2014;141(1):112–9. doi:10.1093/toxsci/kfu109.PubMedPubMedCentralCrossRef

26.

Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84–91.PubMedCrossRef

27.

Gan Y, Liu Q, Wu W, Yin JX, Bai XF, Shen R, et al. Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc Natl Acad Sci U S A. 2014;111(7):2704–9. doi:10.1073/pnas.1315943111.PubMedPubMedCentralCrossRef

28.

Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463–72. doi:10.1016/S0140-6736(08)61619-0.PubMedCrossRef

29.

Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–107. doi:10.1056/NEJMoa1114287.PubMedCrossRef

30.

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–97. doi:10.1056/NEJMoa1206328.PubMedCrossRef

31.

Liu Q, Tang Z, Gan Y, Wu W, Kousari A, La Cava A, et al. Genetic deficiency of beta2-containing nicotinic receptors attenuates brain injury in ischemic stroke. Neuroscience. 2014;256:170–7. doi:10.1016/j.neuroscience.2013.10.049.PubMedCrossRef

32.

Liu H, Wang Y, Xiao Y, Hua Z, Cheng J, Jia J. Hydrogen sulfide attenuates tissue plasminogen activator-induced cerebral hemorrhage following experimental stroke. Transl Stroke Res. 2016;7(3):209–19. doi:10.1007/s12975-016-0459-5.PubMedCrossRef

33.

Liu Y, Tang G, Li Y, Wang Y, Chen X, Gu X, et al. Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion. J Neuroinflammation. 2014;11:177. doi:10.1186/s12974-014-0177-4.PubMedPubMedCentralCrossRef

34.

Zhao P, Zhou R, Zhu XY, Hao YJ, Li N, Wang J, et al. Matrine attenuates focal cerebral ischemic injury by improving antioxidant activity and inhibiting apoptosis in mice. Int J Mol Med. 2015;36(3):633–44. doi:10.3892/ijmm.2015.2260.PubMedPubMedCentral

35.

Hua K, Sheng X, Li TT, Wang LN, Zhang YH, Huang ZJ, et al. The edaravone and 3-n-butylphthalide ring-opening derivative 10b effectively attenuates cerebral ischemia injury in rats. Acta Pharmacol Sin. 2015;36(8):917–27. doi:10.1038/aps.2015.31.PubMedPubMedCentralCrossRef

36.

Lee CH, Yoo KY, Choi JH, Park OK, Hwang IK, Kim SK, et al. Neuronal damage is much delayed and microgliosis is more severe in the aged hippocampus induced by transient cerebral ischemia compared to the adult hippocampus. J Neurol Sci. 2010;294(1-2):1–6. doi:10.1016/j.jns.2010.04.014.PubMedCrossRef

37.

Yaidikar L, Thakur S. Arjunolic acid, a pentacyclic triterpenoidal saponin of Terminalia arjuna bark protects neurons from oxidative stress associated damage in focal cerebral ischemia and reperfusion. Pharmacol Rep. 2015;67(5):890–5. doi:10.1016/j.pharep.2015.02.003.PubMedCrossRef

38.

Ekici F, Karson A, Dillioglugil MO, Gurol G, Kir HM, Ates N. The effects of vagal nerve stimulation in focal cerebral ischemia and reperfusion model. Turk Neurosurg. 2013;23(4):451–7. doi:10.5137/1019-5149.JTN.7114-12.1.PubMed

39.

Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, et al. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur J Neurol. 2015;22(4):664–71. doi:10.1111/ene.12624.PubMedPubMedCentralCrossRef

40.

English C, Aloi JJ. New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther. 2015;37(4):691–715. doi:10.1016/j.clinthera.2015.03.001.PubMedCrossRef

41.

Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. J Med Econ. 2015:1-36. doi:10.3111/13696998.2015.1135805.

42.

Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE. J Clin Invest. 2014;124(5):2188–92. doi:10.1172/JCI72151.PubMedPubMedCentralCrossRef

43.

Milenkovic M, Arsenovic-Ranin N, Vucicevic D, Bufan B, Jancic I, Stojic-Vukanic Z. Beneficial effects of dimethyl fumarate on experimental autoimmune myocarditis. Arch Med Res. 2008;39(7):639–46. doi:10.1016/j.arcmed.2008.07.003.PubMedCrossRef

44.

Robles L, Vaziri ND, Li S, Takasu C, Masuda Y, Vo K, et al. Dimethyl fumarate ameliorates acute pancreatitis in rodent. Pancreas. 2015;44(3):441–7. doi:10.1097/MPA.0000000000000275.PubMedPubMedCentral

45.

Robles L, Vaziri ND, Li S, Masuda Y, Takasu C, Takasu M, et al. Dimethyl fumarate protects pancreatic islet cells and non-endocrine tissue in L-arginine-induced chronic pancreatitis. PLoS One. 2014;9(9):e107111. doi:10.1371/journal.pone.0107111.PubMedPubMedCentralCrossRef

46.

Dibbert S, Clement B, Skak-Nielsen T, Mrowietz U, Rostami-Yazdi M. Detection of fumarate-glutathione adducts in the portal vein blood of rats: evidence for rapid dimethylfumarate metabolism. Arch Dermatol Res. 2013;305(5):447–51. doi:10.1007/s00403-013-1332-y.PubMedCrossRef

47.

Lehmann JC, Listopad JJ, Rentzsch CU, Igney FH, von Bonin A, Hennekes HH, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol. 2007;127(4):835–45. doi:10.1038/sj.jid.5700686.PubMedCrossRef

48.

Koh SH, Park HH. Neurogenesis in stroke recovery. Transl Stroke Res. 2016. doi:10.1007/s12975-016-0460-z

49.

Hanson J, Gille A, Zwykiel S, Lukasova M, Clausen BE, Ahmed K, et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest. 2010;120(8):2910–9. doi:10.1172/JCI42273.PubMedPubMedCentralCrossRef

50.

Digby JE, Martinez F, Jefferson A, Ruparelia N, Chai J, Wamil M, et al. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol. 2012;32(3):669–76. doi:10.1161/ATVBAHA.111.241836.PubMedPubMedCentralCrossRef

51.

Hanson J, Gille A, Offermanns S. Role of HCA(2) (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacol Ther. 2012;136(1):1–7. doi:10.1016/j.pharmthera.2012.06.003.PubMedCrossRef

52.

Rahman M, Muhammad S, Khan MA, Chen H, Ridder DA, Muller-Fielitz H, et al. The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat Commun. 2014;5:3944. doi:10.1038/ncomms4944.PubMedCrossRef

53.

Becker KJ. Strain-related differences in the immune response: relevance to human stroke. Transl Stroke Res. 2016;7(4):303–12. doi:10.1007/s12975-016-0455-9.PubMedCrossRef

54.

Yamasaki Y, Matsuo Y, Matsuura N, Onodera H, Itoyama Y, Kogure K. Transient increase of cytokine-induced neutrophil chemoattractant, a member of the interleukin-8 family, in ischemic brain areas after focal ischemia in rats. Stroke. 1995;26(2):318–22. discussion 22-3.PubMedCrossRef

55.

Ding Y, Chen M, Wang M, Li Y, Wen A. Posttreatment with 11-keto-beta-boswellic acid ameliorates cerebral ischemia-reperfusion injury: Nrf2/HO-1 pathway as a potential mechanism. Mol Neurobiol. 2015;52(3):1430–9. doi:10.1007/s12035-014-8929-9.PubMedCrossRef

56.

Sun J, Ren X, Simpkins JW. Sequential upregulation of superoxide dismutase 2 and heme oxygenase 1 by tert-butylhydroquinone protects mitochondria during oxidative stress. Mol Pharmacol. 2015;88(3):437–49. doi:10.1124/mol.115.098269.PubMedPubMedCentralCrossRef

57.

Han J, Wang M, Jing X, Shi H, Ren M, Lou H. (-)-Epigallocatechin gallate protects against cerebral ischemia-induced oxidative stress via Nrf2/ARE signaling. Neurochem Res. 2014;39(7):1292–9. doi:10.1007/s11064-014-1311-5.PubMedCrossRef

58.

Shi H, Jing X, Wei X, Perez RG, Ren M, Zhang X, et al. S-allyl cysteine activates the Nrf2-dependent antioxidant response and protects neurons against ischemic injury in vitro and in vivo. J Neurochem. 2015;133(2):298–308. doi:10.1111/jnc.12986.PubMedCrossRef

59.

Chen S, Yang Q, Chen G, Zhang JH. An update on inflammation in the acute phase of intracerebral hemorrhage. Transl Stroke Res. 2015;6(1):4–8. doi:10.1007/s12975-014-0384-4.PubMedCrossRef

60.

Sagai M, Tin Win-Shwe T. Oxidative stress derived from airborne fine and ultrafine particles and the effects on brain-nervous system: part 2. Nihon Eiseigaku Zasshi. 2015;70(3):220–9. doi:10.1265/jjh.70.220.PubMedCrossRef

61.

Alhadidi Q, Bin Sayeed MS, Shah ZA. Cofilin as a promising therapeutic target for ischemic and hemorrhagic stroke. Transl Stroke Res. 2016;7(1):33–41. doi:10.1007/s12975-015-0438-2.PubMedCrossRef

62.

Husain K, Hernandez W, Ansari RA, Ferder L. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem. 2015;6(3):209–17. doi:10.4331/wjbc.v6.i3.209.PubMedPubMedCentralCrossRef

63.

Huang Y, Li W, Su ZY, Kong AT. The complexity of the Nrf2 pathway: beyond the antioxidant response. J Nutr Biochem. 2015. doi:10.1016/j.jnutbio.2015.08.001.

64.

Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354(6):588–600. doi:10.1056/NEJMoa052980.PubMedCrossRef

65.

Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357(6):562–71. doi:10.1056/NEJMoa070240.PubMedCrossRef

66.

Bath PM, Gray LJ, Bath AJ, Buchan A, Miyata T, Green AR, et al. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol. 2009;157(7):1157–71. doi:10.1111/j.1476-5381.2009.00196.x.PubMedPubMedCentralCrossRef

67.

Kaste M, Murayama S, Ford GA, Dippel DW, Walters MR, Tatlisumak T, et al. Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovasc Dis. 2013;36(3):196–204. doi:10.1159/000353680.PubMedCrossRef

68.

Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(Pt 3):678–92. doi:10.1093/brain/awq386.PubMedCrossRef

69.

Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Hayashi M, Sekine H, et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun. 2016;7:11624. doi:10.1038/ncomms11624.PubMedPubMedCentralCrossRef

70.

Schulze-Topphoff U, Varrin-Doyer M, Pekarek K, Spencer CM, Shetty A, Sagan SA, et al. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proc Natl Acad Sci U S A. 2016;113(17):4777–82. doi:10.1073/pnas.1603907113.PubMedPubMedCentralCrossRef

71.

Adam J, Hatipoglu E, O’Flaherty L, Ternette N, Sahgal N, Lockstone H, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011;20(4):524–37. doi:10.1016/j.ccr.2011.09.006.PubMedPubMedCentralCrossRef

72.

Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 2011;20(4):511–23. doi:10.1016/j.ccr.2011.08.024.PubMedCrossRef

Title: Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
Authors: Yang Yao
Weimin Miao
Zhijia Liu
Wei Han
Kaibin Shi
Yi Shen
Handong Li
Qiang Liu
Ying Fu
DeRen Huang
Fu-Dong Shi
Publication date: 01-12-2016
Publisher: Springer US
Published in: Translational Stroke Research / Issue 6/2016
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-016-0496-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Integrin β8 Deletion Enhances Vascular Dysplasia and Hemorrhage in the Brain of Adult Alk1 Heterozygous Mice

cPKCγ-Modulated Autophagy in Neurons Alleviates Ischemic Injury in Brain of Mice with Ischemic Stroke Through Akt-mTOR Pathway

A Post-stroke Therapeutic Regimen with Omega-3 Polyunsaturated Fatty Acids that Promotes White Matter Integrity and Beneficial Microglial Responses after Cerebral Ischemia

Secondary Stroke Prevention: Improving Diagnosis and Management with Newer Technologies

Microglia Activation and Polarization After Intracerebral Hemorrhage in Mice: the Role of Protease-Activated Receptor-1

Delayed Docosahexaenoic Acid Treatment Combined with Dietary Supplementation of Omega-3 Fatty Acids Promotes Long-Term Neurovascular Restoration After Ischemic Stroke